The high platelet reactivity is associated with adverse events after stent implantation. Current guidelines consider the measurement of aggregability as a class IIB and there is no information about the routine performance of these measurements. This was a multicenter, prospective, randomized study that included 3800 patients with myocardial infarction. The primary study end point was the incidence of adjustment of the anti-aggregating therapy (dose or drug type) based on test results aggregability. No significant therapy changes were observed, but more often the change of clopidogrel for prasugrel or ticagrelor.
Tracy Wang
2013-10-31
Original title: TRANSLATE-POPS: A Prospective, Cluster-Randomized Trial of Routine Platelet Function Testing in Patients Undergoing PCI
